Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Milan - Delayed Quote EUR

Vertex Pharmaceuticals Incorporated (1VRTX.MI)

431.15
+4.25
+(1.00%)
At close: April 10 at 1:09:49 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
11,020,100
11,020,100
9,869,200
8,930,700
7,574,400
Cost of Revenue
1,530,500
1,530,500
1,262,200
1,080,300
904,200
Gross Profit
9,489,600
9,489,600
8,607,000
7,850,400
6,670,200
Operating Expense
5,094,600
5,094,600
4,826,600
3,600,500
3,891,200
Operating Income
4,395,000
4,395,000
3,780,400
4,249,900
2,779,000
Net Non Operating Interest Income Expense
567,500
567,500
570,600
89,800
-56,600
Other Income Expense
-4,714,000
-4,714,000
28,800
-107,300
8,000
Pretax Income
248,500
248,500
4,379,800
4,232,400
2,730,400
Tax Provision
784,100
784,100
760,200
910,400
388,300
Net Income Common Stockholders
-535,600
-535,600
3,619,600
3,322,000
2,342,100
Diluted NI Available to Com Stockholders
-535,600
-535,600
3,619,600
3,322,000
2,342,100
Basic EPS
-2.08
-2.08
14.05
12.97
9.09
Diluted EPS
-2.08
-2.08
13.89
12.82
9.01
Basic Average Shares
257,900
257,900
257,700
256,100
257,700
Diluted Average Shares
257,900
257,900
260,500
259,100
259,900
Total Operating Income as Reported
-232,900
-232,900
3,832,000
4,307,400
2,782,100
Total Expenses
6,625,100
6,625,100
6,088,800
4,680,800
4,795,400
Net Income from Continuing & Discontinued Operation
-535,600
-535,600
3,619,600
3,322,000
2,342,100
Normalized Income
3,120,441
3,120,441
3,576,978.40
3,276,862.50
2,339,440.20
Interest Income
598,100
598,100
614,700
144,600
4,900
Interest Expense
30,600
30,600
44,100
54,800
61,500
Net Interest Income
567,500
567,500
570,600
89,800
-56,600
EBIT
279,100
279,100
4,423,900
4,287,200
2,791,900
EBITDA
486,300
486,300
4,605,200
4,435,500
2,917,500
Reconciled Cost of Revenue
1,530,500
1,530,500
1,262,200
1,080,300
904,200
Reconciled Depreciation
207,200
207,200
181,300
148,300
125,600
Net Income from Continuing Operation Net Minority Interest
-535,600
-535,600
3,619,600
3,322,000
2,342,100
Total Unusual Items Excluding Goodwill
-4,627,900
-4,627,900
51,600
57,500
3,100
Total Unusual Items
-4,627,900
-4,627,900
51,600
57,500
3,100
Normalized EBITDA
5,114,200
5,114,200
4,553,600
4,378,000
2,914,400
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-971,859
-971,859
8,978.40
12,362.50
440.20
12/31/2021 - 12/1/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ICY.F Incyte Corporation
50.76
+3.59%
 
RGO.F Regeneron Pharmaceuticals, Inc.
515.40
+5.83%
 
TIL Instil Bio, Inc.
20.52
+24.44%
 
ACHV Achieve Life Sciences, Inc.
2.4300
-2.02%
 
GALT Galectin Therapeutics Inc.
1.3400
+0.75%
 
PROK ProKidney Corp.
0.9101
+21.49%
 
ONVO Organovo Holdings, Inc.
2.0400
+1.49%
 
CMND Clearmind Medicine Inc.
0.9764
-2.36%
 
ATAI Atai Life Sciences N.V.
1.5200
+3.40%
 
INCY Incyte Corporation
58.00
+1.08%